Sector News

Sun Pharma to acquire Japan’s Pola Pharma for $1 million

November 27, 2018
Life sciences

Sun Pharmaceutical Industries Ltd has bought Japanese drugmaker Pola Pharma Inc. for $1 million as part of plans to strengthen its global presence in dermatology, the Dilip Shanghvi-promoted pharma major said on Monday.

Part of Pola Orbis group, Pola Pharma is engaged in the research and development, manufacture, sale and distribution of branded and generic products, primarily in dermatology. It has two plants in Saitama, Japan, which can manufacture topical products and injectables, and has annual revenues of approximately $108 million.

“This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us to launch our speciality and generic dermatology products in the Japanese market in future,” Kirti Ganorkar, executive vice-president of Sun Pharma, said in a statement. “We also get access to local manufacturing capability enabling us to serve the Japanese pharmaceutical market more effectively.” Pola Pharma will help Sun launch its speciality and generic dermatology products in Japan in future, he added.

The development comes two years after Sun Pharma, India’s largest drugmaker, entered Japan with the acquisition of 14 established prescription brands from Novartis.

Pola Pharma was valued on a debt-free and cash-free basis, Sun Pharma said, adding it will buy 100% of the Japanese firm’s equity. The deal is expected to close on or before 31 January, subject to completion of closing conditions. Pola Pharma had a net loss of $7 million for the 12 months to December 2017 on a consolidated basis.

Junichi Nakamichi, Sun Pharma’s country head for Japan, said the idea was to combine the Indian firm’s global strengths with Pola Pharma’s local expertise. “By combining Sun Pharma’s global strengths with Pola Pharma’s local expertise, we will have a great opportunity to further strengthen our presence in Japan, especially in the area of dermatology,” he said.

The size of the Japanese pharmaceutical market is estimated at $84.8 billion, accounting for approximately 7.5% of the $1.13 trillion global pharmaceutical market, the Indian company said.

In 2016, a wholly owned subsidiary of Sun Pharma acquired a portfolio consisting of 14 established prescription brands from Novartis in Japan for a cash consideration of $293 million. These brands had combined annualized revenues of approximately $160 million and addressed medical conditions across several therapeutic areas.

On Monday, Sun Pharma shares fell 2.88% to ₹510.65 apiece on the BSE while the benchmark Sensex rose 1.07% to 35,354.08 points.

By Teena Thacker

Source: Live Mint

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach